Biovista’s drug safety search aids clinical outcomes. Interview to Bio-IT World By Kevin Davies June 8, 2011 | Biovista began as a hobby,” admits the company’s eloquent president, Aris Persidis. But after “dabbling” with the firm for a few years, Persidis incorporated the company in the United States in 2005. Headquartered in Charlottesville, Virginia, Biovista … Read More
News
Biovista to present at the Drug Repositioning Conference
CHARLOTTESVILLE, Virginia, June 3, 2011 — Biovista announced today that it is presenting at the Drug Repositioning Conference, San Francisco, on July 13 2011. Biovista’s President, Dr. Aris Persidis, will give a presentation on systematic repositioning using Mechanism of Action. The Drug Repositioning Conference is one of the prime events in this space and has been … Read More
The benefits of drug repositioning
Guest Commentary in Drug Discovery World (DDW) by Aris Persidis, Biovista’s President Spring 2011 Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy sooner, will … Read More
BioWorld: Repurposing: Achilles Heel or Extra Leg to Stand On?
By Anette Breind, BioWorld Insight For Academia or Industry In the private space, Charlottesville, Va.-based Biovista Inc…Biovista has a positioning program that uses a bioinformatics approach to “develop all reasonable opportunities” for a drug, Persidis said, by tracking “without bias,” all biological effects of a compound…But Biovista is also developing its own in-house pipeline of existing … Read More
FirstWord: Drug Combinations: New Rules, New Opportunities
Biovista featured in FirstWorld’s latest report, “Drug Combinations: New Rules, New Opportunities” For years, drug therapy has been built on that basic equation. Yet as genomic biology sheds light on the astonishing intricacy of disease pathology, it is clear that drugs that combine several compounds must be developed in response. According to Biovista president … Read More